{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-006021","form_type":"8-K","ticker":"NXTC","cik":"0001661059","company_name":"NextCure, Inc.","filed_at":"2026-01-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.796344+00:00","generated_at":"2026-05-16T08:27:40.895451+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"NextCure reports $41.8M cash; SIM0505 data Q2 2026, LNCB74 delayed to H2 2026","bullets":["Preliminary cash, cash equivalents and marketable securities of $41.8M as of Dec 31, 2025; runway into H1 2027.","SIM0505 (CDH6 ADC) Phase 1 dose escalation data expected Q2 2026; dose optimization starts H1 2026.","LNCB74 (B7-H4 ADC) higher dose cohorts underway; proof-of-concept data delayed from H1 to H2 2026.","Both programs target gynecological cancers; LNCB74 now includes adenoid cystic carcinoma."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-006021","json":"https://secwatch.observer/filing/0001104659-26-006021.json","markdown":"https://secwatch.observer/filing/0001104659-26-006021.md","text":"https://secwatch.observer/filing/0001104659-26-006021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661059/000110465926006021/0001104659-26-006021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661059/000110465926006021/nxtc-20260123x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T08:27:40.895451+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}